(生物谷Bioon.com) 原文出处:Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和...
Objective: To report efficacy, safety and tolerability of oral vidofludimus calcium (IMU-838) in EMPhASIS (NCT03846219), a phase 2 double-blind, placebo-controlled, randomized, parallel-group trial in relapsing multiple sclerosis (MS).Background: Dihydroorotate dehydrogenase (DHODH) inhibition is ...
Therefore, DHODH inhibition may be broadly applicable against multiple viruses. IMU-838 was successfully tested in two phase 1 clinical trials in 2017 and is currently being tested in phase 2 trials in patients with COVID-19, relapsing-remitting multiple sclerosis and ulcerative colitis. Furthermore...